New Version of Clinical Trial Imaging Management Solution Expands Features for Specific Clinical Areas, Enhances Workflow, Increases Flexibility, and Eases Quality Control Processes
Radiant Sage LLC, a provider of on-demand clinical trial imaging infrastructure solutions, today announced the newest version of its Corelab-in-a-Box™ (CLIB) Clinical Trial Imaging Management technology solution. This new version provides sponsors with the key functionality of an imaging corelab in a web-based solution bringing security, efficiency, speed, and transparency to what was considered a black box industry. CLIB Version 3.1 has expanded its features for specific clinical areas, such as oncology, dermatology and for echocardiography. It also offers enhanced workflow and increased flexibility and has eased the quality control and data clarification processes.
"Each clinical study has its own requirements. In this version of our Clinical Trial Imaging Management solution, we have made significant enhancements by adding features for oncology and other clinical areas that rely heavily on imaging data during their studies," said Ven Thangaraj, CEO of Radiant Sage. "We have listened to our clients and enhanced our product to help them to more easily facilitate study execution, regulatory compliance and exploratory research."
Some of the enhancements in CLIB Version 3.1 include:
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.